Asia Pacific Nuclear Medicine Market Size & Outlook
Global Market
Related Markets
Asia Pacific nuclear medicine market highlights
- The Asia Pacific nuclear medicine market generated a revenue of USD 4,607.7 million in 2025.
- The market is expected to grow at a CAGR of 7.3% from 2026 to 2033.
- In terms of segment, diagnostics was the largest revenue generating product in 2025.
- Diagnostics is the most lucrative product segment registering the fastest growth during the forecast period.
- Country-wise, China is expected to register the highest CAGR from 2026 to 2033.
Asia Pacific data book summary
| Market revenue in 2025 | USD 4,607.7 million |
| Market revenue in 2033 | USD 8,594.5 million |
| Growth rate | 7.3% (CAGR from 2026 to 2033) |
| Largest segment | Diagnostics |
| Fastest growing segment | Diagnostics |
| Historical data covered | 2021 - 2024 |
| Base year for estimation | 2025 |
| Forecast period covered | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Diagnostics, Therapeutics |
| Key market players worldwide | GE HealthCare Technologies Inc Common Stock, Jubilant Pharmova, Nordion, Bracco, Iren SpA, Abliva AB, Lantheus Holdings Inc, Eckert & Ziegler Bebig SA, Mallinckrodt PLC Ordinary Shares - New, Cardinal Health Inc |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 21.7% of the global nuclear medicine market in 2025.
- Globally, North America is projected to lead the regional market in terms of revenue in 2033.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 8,594.5 million by 2033.
The market in Asia Pacific is expected to grow at the fastest rate during the forecast period owing to the increasing geriatric population and rising healthcare expenditure in developing countries such as China and India.
Moreover, development of radiopharmaceuticals for the diagnosis and treatment of various diseases is likely to further boost market growth in this region. For instance, in August 2018, Indonesia’s National Nuclear Agency (BATAN), along with IAEA, developed a new radiopharmaceutical (99mTc-ethambutol) for the diagnosis of tuberculosis.
In addition, presence of local companies such as ANSTO, Fuzionaire Radioisotope Technologies K.K., and Chengdu Gaotong Isotope Co., Ltd., in the region to develop imaging agents for diagnosis & treatment of cancer, cardiological disorder, neurological diseases, & others is anticipated to boost market growth.
No credit card required*
Publish Date: Jun 17, 2026
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Nuclear Medicine Market Scope
Nuclear Medicine Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| GE HealthCare Technologies Inc Common Stock | View profile | 51,000 | 500 West Monroe Street, Chicago, IL, United States, 60661 | www.gehealthcare.com |
| Cardinal Health Inc | View profile | 48,000 | 7000 Cardinal Place, Dublin, OH, United States, 43017 | www.cardinalhealth.com |
| Mallinckrodt PLC Ordinary Shares - New | View profile | 2,700 | College Business and Technology Park, Cruiserath, Blanchardstown, Dublin, Ireland, 15 | www.mallinckrodt.com |
| Eckert & Ziegler Bebig SA | View profile | 501-1000 | Seneffe, Hainaut, Belgium, Europe | www.ezag.com/home/ |
| Nordion | View profile | 251-500 | Kanata, Ontario, Canada, North America | nordion.com |
| Bracco | View profile | 1001-5000 | Milan, Lombardia, Italy, Europe | www.bracco.com |
| Lantheus Holdings Inc | View profile | 834 | 201 Burlington Road, South Building, Bedford, MA, United States, 01730 | www.lantheus.com |
| Jubilant Pharmova | View profile | 10001+ | Noida, Uttar Pradesh, India, Asia | www.jubilantpharmova.com |
| Iren SpA | View profile | 10,000 | Via Nubi di Magellano, 30, Reggio Emilia, Italy, 42123 | www.gruppoiren.it |
| Abliva AB | View profile | 6 | Scheeletorget 1, Medicon Village, Lund, Sweden, 223 81 | www.abliva.com |
Asia Pacific Nuclear Medicine Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Nuclear Medicine Market Outlook will help companies and investors design strategic landscapes.
Diagnostics was the largest segment with a revenue share of 87.75% in 2025.
Horizon Databook has segmented the Asia Pacific nuclear medicine market based on diagnostics, therapeutics covering the revenue growth of each sub-segment from 2021 to 2033.
The market in Asia Pacific is expected to grow at the fastest rate during the forecast period owing to the increasing geriatric population and rising healthcare expenditure in developing countries such as China and India.
Moreover, development of radiopharmaceuticals for the diagnosis and treatment of various diseases is likely to further boost market growth in this region. For instance, in August 2018, Indonesia’s National Nuclear Agency (BATAN), along with IAEA, developed a new radiopharmaceutical (99mTc-ethambutol) for the diagnosis of tuberculosis.
In addition, presence of local companies such as ANSTO, Fuzionaire Radioisotope Technologies K.K., and Chengdu Gaotong Isotope Co., Ltd., in the region to develop imaging agents for diagnosis & treatment of cancer, cardiological disorder, neurological diseases, & others is anticipated to boost market growth.
- Asia Pacific Nuclear Medicine Market Product Outlook (Revenue, USD Million , 2021-2033)
- Diagnostics
- Therapeutics
- Asia Pacific Nuclear Medicine Market Application Outlook (Revenue, USD Million , 2021-2033)
- Cardiology
- Neurology
- Oncology
- Thyroid
- Lymphoma
- Bone Metastasis
- Endocrine Tumor
- Pulmonary Scans
- Urology
- Other
- Asia Pacific Nuclear Medicine Market End Use Outlook (Revenue, USD Million , 2021-2033)
- Hospitals
- Diagnostic Centers
- Others
Reasons to subscribe to Nuclear Medicine Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Nuclear Medicine Market Outlook databook
- Our clientele includes a mix of Nuclear Medicine Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific Nuclear Medicine Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific Nuclear Medicine Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Asia Pacific Nuclear Medicine Market, 2021-2033 (US$M)
Asia Pacific nuclear medicine market statistics, by product, 2021-2033 (US$M)
